Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
Pre-Approval Access Named Patient Program for Talquetamab (JNJ-64407564) for Treating Physician Use in Relapsed or Refractory Multiple Myeloma
2 other identifiers
expanded_access
N/A
0 countries
N/A
Brief Summary
The purpose of this pre-approval access program is to give talquetamab monotherapy (treatment with single drug) to participants with relapsed or refractory multiple myeloma (a type of cancer that begins in plasma cells \[white blood cells that produce antibodies\] which has returned or difficult to treat) who have relapsed on or are refractory to all locally available and clinically appropriate treatment and who are not eligible for a clinical trial.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 14, 2022
CompletedFirst Posted
Study publicly available on registry
March 7, 2023
CompletedDecember 9, 2025
December 1, 2025
December 14, 2022
December 8, 2025
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- Participant diagnosed with relapsed or refractory multiple, myeloma
- Participant exhausted all commercially approved and clinically appropriate treatment options, and is ineligible for a clinical trial
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Janssen Research & Development, LLC Clinical Trial
Janssen Research & Development, LLC
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 14, 2022
First Posted
March 7, 2023
Last Updated
December 9, 2025
Record last verified: 2025-12